New combo therapy aims to tame aggressive lymphoma
NCT ID NCT05495464
First seen Mar 05, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This early-phase study tests whether giving two drugs (acalabrutinib and rituximab) followed by a special immune cell treatment (brexucabtagene autoleucel, a type of CAR T-cell therapy) can help control high-risk mantle cell lymphoma that hasn't been treated before. About 22 people will take part. The main goal is to see if the treatment is safe and to check for serious side effects within 30 days after the cell infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.